Release Date: 25-Jan-2025
YL-201 is an antibody-drug conjugate (ADC) developed by MediLink, a biopharmaceutical company from China, utilizing its proprietary TMALIN platform. This innovative platform aims to overcome the limitations of current ADC technologies by enhancing targeting and effectiveness. YL-201 specifically targets B7-Homologue 3 (B7-H3), a transmembrane glycoprotein that is overexpressed in numerous tumors and immune cells within the tumor microenvironment. B7-H3 is instrumental in cancer progression, influencing tumor cell proliferation, metastasis, and resistance to therapies, thus making it a compelling target for cancer treatment. Upon binding to cells that express B7-H3, YL-201 delivers a cytotoxic agent to the tumor cells, with the goal of inhibiting their growth and promoting cell death.
Download Insight: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
At this time, YL-201 is undergoing Phase 2 clinical trials in China aimed at treating solid tumors that express B7-H3. These trials are dedicated to evaluating the safety and efficacy of YL-201 as a potential therapeutic option for various cancers characterized by elevated B7-H3 levels.